This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...
Investors lose their appetite for the obesity trade
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...
Crackdown on Ozempic, Wegovy Hits Thousands In Colorado
Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.
BMJ16h
Can weight loss drugs like Ozempic treat obesity in children?
GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger people? Katharine Lang reports Obesity in children and adolescents is a ...
Ozempic’s health benefits keep growing, but are the risks worth it?
A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
THESE MEDICATIONS ARE MOSTLY KNOWN FOR TREATING DIABETES AND OBESITY.. BUT THE F-D-A HAS APPROVED THEM FOR PREVENTING HEART DISEASE AFTER STUDIES LAST FALL. THAT SHOWED ABOUT A 20% REDUCTION IN ...
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook
Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...
Ozempic and Wegovy: Scientists Uncover New Risks of Popular Weight-Loss “Miracle Drugs”
GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...